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Most cases of primary salivary mucosa-associated lymphoid
tissue lymphoma are associated either with Sjoegren syndrome
or hepatitis C virus infection
Mucosa-associated lymphoid tissue (MALT) lymphomas rep-
resent about 8% of all non-Hodgkin’s lymphoma (NHL) cases
and involve preferentially the gastrointestinal (GI) tract,
mainly the stomach (Isaacson, 1999). Non-gastrointestinal
(non-GI) MALT lymphoma may arise at different sites, such as
salivary glands, respiratory tract, thyroid, ocular adnexa,
breast, skin, kidney, liver, etc. (Cavalli et al, 2001). MALT
lymphomas present frequently as localized, indolent disease,
predominantly in adult patients (aged over 50 years), with
female predominance (Thieblemont et al, 1997). They usually
arise in response to infectious or autoimmune conditions, such
as Helicobacter pylori (HP) infection in the stomach, Hashi-
moto thyroiditis in the thyroid gland and lymphoepithelial
sialadenitis (LESA), mostly associated with the Sjoegren’s
syndrome (SS), in the salivary glands (Cavalli et al, 2001).
Moreover, a high incidence of hepatitis C virus (HCV)
infection (50%) has been reported in patients affected by
MALT lymphoma (Luppi et al, 1996).
MALT lymphoma is the most frequent histotype among the
primary lymphoma of salivary glands (PSGL), which represent
1Æ7–8Æ6% of all salivary gland tumours and about 1% of all
NHL cases (Gleeson et al, 1986; Sarris et al, 1997; Zucca et al,
1999). Although salivary glands are one of the main sites
involved by non-GI MALT lymphoma, salivary gland MALT
lymphomas (SGML) are infrequent, and data available
concerning their clinical behaviour and the best treatment
are scanty (Takahashi et al, 1992; Balm et al, 1993; Shi et al,
2001).
We report 33 consecutive cases of primary SGML observed
in our Institutions, in order to assess their clinical features at
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Summary
Salivary gland mucosa-associated lymphoid tissue (MALT) lymphomas
(SGML) are rare, as are data concerning their behaviour. We analysed clinical
features at presentation, particularly the association with Sjoegren syndrome
(SS) and hepatitis C virus (HCV) infection, and outcome in 33 cases of
SGML diagnosed between March 1985 and April 2003. There were five males
and 28 females, with a median age of 61 years. At presentation, 12/33 (36%)
had multiple salivary glands or mucosal involvement and four had bone
marrow infiltration. Ann Arbor stage was IE in 15 (46%), IIE in four (12%)
and IV in 14 patients (42%). Fifteen patients had a history of SS (46%), two
of other autoimmune diseases, seven of HCV infection. No case had both SS
and HCV. Of the 29 treated patients, 17 received surgery or local
radiotherapy; 69% achieved complete remission. Histological
transformation occurred in four (12%). Five patients died (three of
lymphoma, two of unrelated causes). The 5 year-overall survival (OS),
cause-specific survival and progression-free survival was 85 ± 8%, 94 ± 6%
and 65 ± 10% respectively. Overall, the disease course was indolent, despite
the advanced stage at diagnosis, and local therapy often appeared to be
adequate. The only prognostic factors influencing OS were histological
transformation and age. The close association of SGML with either
autoimmune diseases or HCV infection in our series (73%) confirms their
possible role in the pathogenesis of these lymphomas.
Keywords: mucosa-associated lymphoid tissue lymphomas, salivary glands,
Sjoegren syndrome, hepatitis C virus infection, prognostic factors.
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presentation, the association with coexisting disorders, the
course of the disease and the response to therapy.
Methods
We retrospectively evaluated 33 patients affected by primary
SGML consecutively observed in our Institutions between
March 1985 and April 2003. The diagnosis of lymphoma was
made by histological and immunohistochemical examination
of salivary tissue, obtained either by surgical biopsy or complete
surgical resection. Histological diagnosis was made or revised,
by multiple pathological review, according to the Revised
European-American Lymphoma (REAL)/World Health Organ-
ization (WHO) classifications (Harris et al, 1994, 2000), with
the aid of immunohistochemical markers (CD20, CD5, CD21,
CD10, CD3, kappa/lambda light chains), performed using
standardized methods and reagents (all purchased from
DakoCytomation, Glostrup, Denmark). The pattern of expres-
sion of the different antigens tested is summarized in Table I.
Cases were considered primary SGML if the salivary
involvement was clinically predominant, requiring diagnostic
investigation, and primary treatment (Zucca et al, 2003).
Staging procedure
Clinical staging at diagnosis included complete physical
examination, routine laboratory (erythrocyte sedimentation
rate, full blood count with differential, biochemical profile,
serum protein electrophoresis), chest X-ray, neck and abdom-
inal ultrasound, thoracic and abdominal computed tomogra-
phy scan. Lactate dehydrogenase (LDH) serum levels were
tested in 28/33 cases. A bone marrow biopsy was performed in
31/33 cases. Eighteen patients underwent oesophagogastro-
duodenoscopy (EGDS) with multiple biopsies. All patients
were evaluated for the possible association with autoimmune
diseases; serology for HCV was tested in 26 patients:
performance status (PS) was evaluated according to the
Eastern Cooperative Oncology Group (ECOG) scale. Patients
were staged according to the original Ann Arbor classification
(Carbone et al, 1971). Cases were assigned to an International
Prognostic Index (IPI) risk group according to the published
criteria (Shipp et al, 1993).
After treatment all initial disease parameters were evaluated
by physical examination, imaging and/or endoscopic studies
when required. Bone marrow biopsy was repeated when
involved at diagnosis.
Treatment modalities
Four patients were not treated initially. One refused treatment;
in the remaining three cases a ‘watch and wait’ policy was
decided. Primary treatment was local in 17 patients: surgical
resection in 13 (followed by radiotherapy in five) and local
radiotherapy alone in four cases (42–50 Gy). Chemotherapy
was administered in 11 patients: alone in eight cases, after
surgery in one and in combination with surgery and radiother-
apy in two (in seven cases a single alkylating agent was used and
four cases were treated with a cyclophosphamide, hydrox-
ydaunomycin, oncovin, prednisone (CHOP)-like regimen).
One patient with associated chronic hepatitis C received
a-interferon therapy 3 million units (MU)/three times weekly
for 6 months and than 5 MU/three times weekly for 11 months.
Analyses
Complete remission (CR) was defined as the complete disap-
pearance of all clinical evidence of lymphoma. Partial response
(PR) was defined as >50% regression. Stable disease (SD) was
defined as a <50% decrease or <50% increase of the known sites
of disease. Relapsing or progressive disease (PD) was defined as
the appearance of any new lesion or increase of at least 50% in
size of the previously involved sites. Overall survival (OS) was
defined as the time from diagnosis to death or last follow-up.
Cause-specific survival (CSS) was measured from diagnosis to
the time of death from disease or treatment-related causes.
Progression-free survival (PFS) was measured from the date of
first line treatment, or of diagnosis in untreated patients, to the
date of first progression or last follow-up.
The patient characteristics at diagnosis that were analysed to
determine any influence on survival were: sex, age, stage, PS, B
symptoms, IPI, multiple involvement of salivary glands or
other multiple mucosal sites, lymph nodes and bone marrow
involvement, Hb levels, LDH serum levels, associated diseases
(autoimmune disease and HCV infection). We also evaluated
the impact on the outcomes of the type of treatment, the
achievement of CR and the histological transformation in
high-grade lymphoma.
Overall survival, CSS, and PFS curves were estimated
according to Kaplan–Meier method. The associations with
prognostic factors were tested using the log-rank test. Multi-
variate analysis was not performed because of the low number
of events.
Results
Patients characteristics
Pretreatment characteristics of the 33 patients are summarized
in Table II.
Table I. Immunohistochemical findings in 33 cases of SGML.
Antigen CD20 CD5 CD10 CD21 CD3
Cy light
chain*
Tested cases (n) 33 30 22 18 28 24
Positive 33 (100%) 0 0 3 (17%) 0 17 (71%)
*Restricted light chain cytoplasmic expression in plasmacell and/or
lymphoplasmacytoid elements (j+ 15 cases; k+ 2 cases).
SGML, salivary gland mucosa-associated lymphoid tissue lymphomas.
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Median age at diagnosis was 61 years (range 21–81). There
were five males and 28 females (ratio 0Æ2). In all patients the
presenting symptom was a solid, indolent mass. Ann Arbor
stage was IE in 15 (46%), IIE in four (12%) and IV in 14
(42%). The primary sites involved by the lymphoma are
detailed in Table III. The majority of patients (64%) had single
salivary gland involvement, mainly of the parotid (52%).
Lymph nodes involvement was present at diagnosis in nine
patients (locoregional in seven, mediastinal and/or abdominal
in two). EGDS, performed in 18 patients, demonstrated
lymphomatous infiltration of the stomach, with MALT
histology, in one case (HP-negative).
Fifteen patients had a history of SS, one of scleroderma and
one of rheumatoid arthritis. Of the 26 patients tested, seven
were HCV antibody (Ab) positive and six were diagnosed with
a chronic hepatitis; none of the autoimmune disease patients
tested for HCV serology (14/17) was HCV-Ab positive.
A serum monoclonal component (IgG or IgM) was docu-
mented in eight cases (25%). In 11/15 (73%) tested cases
cryoglobulinaemia was detectable. Of these 11 patients with
cryoglobulinaemia, five were HCV-Ab positive and six were
affected by SS.
Treatment
One of the four patients who did not receive initial treatment
progressed locally after 82 months, three remained stable with
follow-up durations of 86, 6 and 5 months.
After first-line therapy, 20 of the 29 treated patients achieved
a CR (69%), seven a PR (24%), one did not respond and one is
not yet evaluable. Among patients with stage I–II, CR was
obtained in 13/14 cases (93%) receiving local treatment alone
(surgery and/or radiotherapy) and in 2/2 treated also with
additional chemotherapy. Of the remaining stage I–II patients,
one received chemotherapy only and achieved a PR, two were
not treated. Three of the seven evaluable stage-IV patients
treated with chemotherapy achieved a CR, three a PR and one
did not respond. Two were not treated and three had only
surgical excision. The patient treated at diagnosis with
a-interferon obtained a PR; at the end of treatment HCV-
RNA was still positive.
Twelve patients (36%) experienced relapsing or PD after
6–90 months (median 24). In two cases it occurred at the
original sites, in three at the controlateral parotid; one patient
with involvement of minor salivary glands relapsed in the right
Table II. Pretreatment characteristics of the 33 patients with SGML.
Features No. of patients (%)
Age (years)
<60 16 (48)
‡60 17 (52)
Sex
Male 5 (15)
Female 28 (85)
Performance status (ECOG)
0–1 32 (97)
‡2 1 (3)
Ann Arbor Stage
IE 15 (46)
IIE 4 (12)
IV 14 (42)
B symptoms
Absent 32 (97)
Present 1 (3)
Single salivary gland involvement 21 (64)
Multiple salivary glands or multiple
MALT involvement
12 (36)
Bone marrow involvement
Absent 27 (82)
Present 4 (12)
Unknown 2 (6)
Nodal involvement
Absent 24 (73)
Present 9 (27)
Hb ‡ 12 g/dl 24 (73)
Hb < 12 g/dl 9 (27)
Serum LDH levels
Normal 24 (73)
Increased 4 (12)
Unknown 5 (15)
International Prognostic Index
Low to low/intermediate risk 19 (58)
Intermediate/high to high risk 9 (27)
Unknown 5 (15)
HCV serology
Positive 7 (21)
Negative 19 (58)
Unknown 7 (21)
Associated autoimmune disease
Sjogren syndrome 15 (46)
Scleroderma 1 (3)
Rheumatoid arthritis 1 (3)
SGML, salivary gland mucosa-associated lymphoid tissue (MALT)
lymphomas; ECOG, Eastern Cooperative Oncology Group; LDH,
lactate dehydrogenase; HCV, hepatitis C virus.
Table III. Initial mucosal sites involved in 33 cases of SGML.
Patients,
n (%)
One salivary gland involvement 21 (64)
Parotid 17 (52)
Submandibular 2 (6)
Minor salivary glands 2 (6)
Multiple salivary glands or multiple MALT involvement 12 (36)
Parotid bilateral 4 (12)
Parotid + submandibular 5 (15)
Parotid + minor salivary glands 1 (3)
Parotid bil + submandibular bil + stomach 1 (3)
Parotid + lacrimal gland 1 (3)
SGML, salivary gland mucosa-associated lymphoid tissue (MALT)
lymphomas.
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parotid and skin, one in the lung, one in the stomach and four in
the lymph nodes (locoregional in three and abdominal in one).
Histological transformation to large B-cell lymphoma
occurred in 4/33 (12%) patients at 35, 57, 67 and 110 months
from diagnosis. In one case this represented the first sign of
disease progression.
Survival
The median duration of follow-up was 59 months (range
5–143). At the time of follow-up, 28 (85%) patients were alive,
three had died of disease progression (60, 82 and 137 months
from diagnosis), and two of unrelated causes. All of the
patients that died of disease progression showed histological
transformation.
The estimated 5-year OS, CSS and PFS of all patients was
85 ± 8%, 94 ± 6% and 65 ± 10% respectively (Fig 1).
Analysis of prognostic factors
When univariate analysis was performed age >60 years was
associated with poorer OS (P ¼ 0Æ02), but not CSS (P ¼ 0Æ09)
and PFS (P ¼ 0Æ24).
The 5-year OS for the nine patients with lymphnodal
involvement at diagnosis was 50 ± 25% vs. 94 ± 5% for the
remaining patients. This difference was not statistically signi-
ficant (P ¼ 0Æ06). CSS and PFS were not influenced by
lymphnodal involvement (P ¼ 0Æ12 and 0Æ54 respectively).
Increased serum LDH levels were associated with a poorer
5-year PFS (37 ± 28% vs. 78 ± 10% of the patients with
normal LDH; P ¼ 0Æ01). Serum LDH levels did not influence
either OS or CSS.
Gender, Ann Arbor stage IV, impaired PS, bone marrow
involvement, multiple involvement of salivary glands or of
multiple MALT organs, intermediate/high risk IPI, anaemia,
HCV infection or autoimmune disease were not associated
with poorer survival.
Overall survival and CSS were not influenced by the
achievement of CR. OS, CSS and PFS rate did not differ
according to the type of first-line therapy (local or systemic).
Overall survival was significantly affected by histological
transformation to high-grade lymphoma: the 5-year and
10-year OS of the four patients who experienced histological
transformation were 66 ± 33% and 33 ± 27% respectively,
and was significantly lower than those of the 29 remaining
patients (88 ± 8% at 5 and 10 years, P ¼ 0.04). The relative
risk of death was 7Æ84 (95% confidence interval: 1Æ31–47Æ0).
The only two variables significantly associated with the
occurrence of histological transformation into high-grade
lymphomas were age >60 years (P ¼ 0Æ04) and lymphnodal
involvement at presentation (P ¼ 0Æ007). In particular, in the
nine cases with nodal involvement the probability of histo-
logical transformation was 43% at 5 years vs. 7% for the
remaining patients.
Discussion
Primary salivary glands lymphoma is an infrequent neoplasm
that usually occurs in the parotid glands. According to the
REAL/WHO classification, most of these lymphomas are
classifiable as marginal-zone B-cell lymphoma, extranodal,
MALT type. Our series of 33 patients with SGML is one of the
largest reported to date. Published series described seven to 32
cases of SGML, and some of them are pathological studies
(Takahashi et al, 1992; Balm et al, 1993; Thieblemont et al,
1997; Zinzani et al, 1999; Shi et al, 2001; Tsang et al, 2001;
Wenzel et al, 2003). The largest report of non-GI MALT
lymphomas (180 cases) recently published by Zucca et al
(2003), and collected from various centres, included 46 SMGL,
but clinical data concerning lymphomas arising in the salivary
glands are limited.
In the majority of our patients with SGML (24/33–73%) the
lymphoma was associated with either SS (15 cases) or other
autoimmune disease (one rheumatoid arthritis and one
scleroderma) or HCV infection (seven cases); in no case did
the autoimmune disease coexist with HCV infection. Four of
the remaining nine patients were not tested for HCV serology.
The association of PSGL with SS and LESA has been
extensively reported. Approximately 20% of PSGL are associ-
ated with SS or LESA (Barnes et al, 1998; Harris, 1999).
SS/LESA patients have a 44-fold increased risk of developing
salivary or extrasalivary lymphoma, 48–75% of which are of
marginal zone/MALT type (Kassan et al, 1978; Royer et al,
1997; Harris, 1999; Voulgarelis et al, 1999). In salivary gland
Fig 1. Overall survival (OS), cause-specific sur-
vival (CSS) and progression-free survival (PFS)
of 33 patients with salivary gland mucosa-asso-
ciated lymphoid tissue lymphomas.
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biopsies revealing LESA-like lesions, various studies found that
between 25% and 80% had morphological and/or immuno-
phenotypical evidence of low-grade MALT lymphoma (Hyjek
et al, 1988; Takahashi et al, 1992; Harris, 1999).
Our study confirms the association of SGML with SS, but
with a higher rate (46%) when compared with others reports
of SGML or PSGL (Takahashi et al, 1992; Balm et al, 1993;
Barnes et al, 1998). However, a significant association
between SS and SGML was also recently reported by Zucca
et al (2003).
In our series, 29% of the patients with SGML had positive
serology for HCV (seven of 24 tested patients). The reported
HCV seroprevalence rate in northern Italy adult general
population is 3Æ3–3Æ5% (Campello et al, 2002; Mazzeo et al,
2003). An association between HCV infection and B-cell
lymphoma has been largely demonstrated in several geograph-
ical areas, with a rate ranging between 7Æ4% and 37%
(Zuckerman & Zuckerman, 2002). Among the non-GI MALT
lymphomas, an association with HCV infection was recently
reported for MALT lymphoma localized in the parotid gland
(Zucca et al, 2003). HCV RNA and HCV-related antigens have
been detected in the epithelial cells of salivary glands of HCV-
positive patients and in residual epithelial structures in a NHL
of the parotid (De Vita et al, 1995; Arrieta et al, 2001). The
chronic sialadenitis, characteristic of SS and demonstrated in
many HCV-infected patients (Haddad et al, 1992; Scott et al,
1997), could represent a first ‘stimulus’ in the aetiopathogen-
esis of SGML.
Lymphomas complicating SS share a number of features
with lymphomas complicating HCV infection (Ferri et al,
1994; Zuckerman & Zuckerman, 2002): mucosal localization,
marginal zone histologic subtype, associated cryoglobulinae-
mia. In both diseases it has been hypothesized that the first
event of lymphomagenesis could be a chronic stimulation, at
the site of the disease, of polyclonal B-cells secreting
rheumatoid factor (RF), from which a monoclonal population
could arise (Mariette, 1999). The next step would be the
acquisition of chromosomal abnormalities leading to trans-
formation into MALT lymphoma (Cavalli et al, 2001; Streubel
et al, 2003). A last event (e.g. mutation of p53) could
transform this low grade B-cell lymphoma into a high-grade
large B-cell lymphoma (Du & Isaacson, 2002).
The median age of our patients (61 years) was similar to
that reported in other series of non-GI MALT lymphoma
(Thieblemont et al, 1997; Zinzani et al, 1999; Zucca et al,
2003) and SGML (Balm et al, 1993; Shi et al, 2001).
A prevalence of female patients was reported in the majority
of non-GI MALT lymphoma series (Thieblemont et al, 1997;
Zinzani et al, 1999; Liao et al, 2000; Sancho et al, 2000; Zucca
et al, 2003), although our male/female ratio of 0Æ2 appears
quite lower.
The percentage of Ann Arbor stage IV in our series (42%),
mainly depending on the involvement of other salivary glands
or MALT organs (10/14), was comparable with that reported
by other non-GI MALT lymphomas series (Thieblemont et al,
1997; Zinzani et al, 1999) (34% and 37% respectively), and
higher than that reported by Zucca et al (2003) (27%). Bone
marrow infiltration was present in 12% of our patients,
similarly to that reported in these series.
Both GI and non-GI MALT lymphomas are known to have
an indolent natural course, irrespective of multiorgan involve-
ment at diagnosis, and a favourable outcome. This is
confirmed by our study. The 5-year OS and CSS rates of
85 ± 8% and 94 ± 6% respectively, are comparable with those
reported in other series of non-GI MALT lymphomas (Thie-
blemont et al, 1997; Zinzani et al, 1999; Liao et al, 2000;
Sancho et al, 2000; Zucca et al, 2003), despite the high
percentage of advanced stage (IV) patients in our series.
The PFS rate was 65 ± 10%, similar to that reported by
Zucca et al (2003) for SGML (67%).
Generally MALT lymphomas tend to diffuse to other sites
within the organ of origin or to other MALT-containing
organs (Isaacson, 1995; Thieblemont et al, 2000). In addition
in our series relapse or progression occurred locally, i.e. in
salivary glands or locoregional nodes, in the majority of cases
(9/12 cases; 75%). The prognosis did not seem to be influenced
by the spreading to other MALT organs. The adverse influence
on OS of the lymphnodal involvement was not statistically
significant in our series, probably because of the limited
number of patients (P ¼ 0Æ06). However, lymphnodal involve-
ment appeared to represent an adverse prognostic factor for
non-GI MALT lymphomas in the recent report by Zucca et al
(2003).
Transformation to high-grade lymphoma was observed in
12% (4/33) of our patients and represented a late event
(median 62 months after diagnosis). This rate of transforma-
tion is similar to that reported in non-GI MALT lymphomas
by Thieblemont et al (1997) (19%) and higher than those
reported by Zucca et al (2003) (3%), Zinzani et al (1999) (0%)
and Wenzel et al (2003) (3%), probably because of different
follow-up.
In our series all disease-related deaths occurred in patients
who underwent histological transformation to high-grade
lymphoma: this event significantly influenced the OS. Histo-
logical transformation was significantly influenced by age and
lymphnodal involvement at presentation. Dissemination to the
lymph nodes could correspond to tumour progression and
precede transformation to high-grade lymphoma.
The optimal therapeutic strategy in SGML has not yet been
clearly defined. Our patients were treated by various means,
the majority of them (59%) having received surgery and/or
radiotherapy. In our series no significant differences in OS,
CSS and PFS were found according to local or systemic
treatment modalities, in agreement with Thieblemont et al
(1997). The higher CR rate obtained with local therapy in the
initial stages did not correspond to a better outcome.
Aggressive therapy does not seem to be indicated in most
cases of SGML, with the possible exception of those with
lymphnodal involvement. A recent report indicated a signifi-
cant activity and safety of immunotherapy with Rituximab in
Salivary MALT Lymphoma, Sjoegren Syndrome and HCV Infection
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MALT lymphomas (Conconi et al, 2003), suggesting a possible
role of this kind of therapy also in SGML.
In conclusion, our series of SGML, which can be considered
one of the largest published to date, confirms that SGML
preferentially occur in elderly women and have an indolent
course regardless of treatment type, in spite of the high
percentage of advanced stages. Similarly to other non-GI
MALT lymphoma, SGML diffuse preferentially to various
mucosal sites, but this does not seem to influence outcome.
Histological transformation and age appear the only adverse
prognostic factors for OS.
Among the non-GI MALT lymphomas, SGML are charac-
terized by a close association with SS (or other autoimmune
disease) or HCV infection. This association, already reported
by Zucca et al (2003), was strengthened by our study.
Autoimmune diseases and HCV infection appeared mutually
exclusive and were present in the majority (73%) of our
patients, thus confirming the pathogenetic link between
MALT lymphomas and chronic infections or autoimmune
diseases.
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